GLPG Galapagos NV

Transparency notification received from The Capital Group

Transparency notification received from The Capital Group

Mechelen, Belgium; 4 May 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc.

Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 30 April 2021 from The Capital Group Companies, Inc., who notified that it holds 4.65% of the current 65,511,581 outstanding Galapagos shares. The Capital Group Companies, Inc. thus crossed below the 5% threshold of Galapagos’ voting rights by disposing of voting securities on 29 April 2021. The full transparency notice is available on the Galapagos website.

About Capital Group

Capital Group controls Capital Bank & Trust Company and Capital Research & Management Company through its direct subsidiary Capital Group International, Inc. (“CGII”), controls four CGII investment management companies (Capital International, Inc.; Capital International Limited, Capital International Sàrl; and Capital International K.K.), which all together hold 3,049,333 of Galapagos’ voting rights, consisting of ordinary shares, which represents 4.65%.

About Galapagos

Galapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at .

Contacts



Investors:

Elizabeth Goodwin

VP Investor Relations

Sofie Van Gijsel

Senior Director Investor Relations

5

Media:

Carmen Vroonen

Global Head Communications & Public Affairs

Kyra Obolensky

Senior Director Corporate Communications

5


1  Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market

Attachment



EN
04/05/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galapagos NV

 PRESS RELEASE

Galapagos Creates New Subscription Right Plan

Galapagos Creates New Subscription Right Plan Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its  Board of Directors created 1,800,000 subscription rights under a new subscription right plan. On August 7, 2025, the Board of Directors of Galapagos approved “Subscription Right Plan 2025 (B)”, intended for personnel of the Company and its subsidiaries, within the framework of the authorized capital. Under this subscription right plan, 1,800,000 subscription rights were created, subject to acceptance, for senior...

 PRESS RELEASE

Galapagos creëert nieuw inschrijvingsrechtenplan

Galapagos creëert nieuw inschrijvingsrechtenplan Mechelen, België; 7 augustus 2025, 22.01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt vandaag aan dat haar Raad van Bestuur 1.800.000 inschrijvingsrechten heeft gecreëerd onder een nieuw inschrijvingsrechtenplan. De Raad van Bestuur van Galapagos heeft op 7 augustus 2025 “Inschrijvingsrechtenplan 2025 (B)”, bestemd voor leden van het personeel van de Vennootschap en van haar dochtervennootschappen, goedgekeurd binnen het kader van het toegestaan kapitaal. Onder dit inschrijvingsrechtenplan werden 1.80...

Jacob Mekhael
  • Jacob Mekhael

Galapagos Receives FDA RMAT designation for GLPG5101 in r/r MCL

Galapagos announced that the FDA has granted RMAT designation to GLPG5101 (CD19- CAR-T) to treat relapsed/refractory mantle cell lymphoma (r/r MCL). This is based on the strong data that GLPG5101 has demonstrated in the MCL cohort in the phase 1/2 (ATLANTA-1) trial in r/r NHL, and comes with a number of potential benefits including eligibility for accelerated approval, and could further support external discussions as Galapagos explores strategic alternatives for the cell therapy business. Accum...

 PRESS RELEASE

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy...

Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FDA) has granted RMAT designation to GLPG5101, a second generation anti-CD19/4-1BB CAR-T product candidate for the treatment of relapsed/refractory mantle cell lymphoma (R/R MCL).  The RMAT designation was established under th...

 PRESS RELEASE

Galapagos NV kondigt aan dat GLPG5101 de status van Regenerative Medic...

Galapagos NV kondigt aan dat GLPG5101 de status van Regenerative Medicine Advanced Therapy (RMAT) van de FDA krijgt voor de behandeling van recidief/refractair mantelcellymfoom Mechelen, België; 6 augustus 2025, 7.30 uur CET; gereglementeerde informatie – voorwetenschap – Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag aan dat de Amerikaanse Food and Drug Administration (FDA) de RMAT-status heeft toegekend aan GLPG5101, een tweede generatie anti-CD19/4-1BB CAR-T kandidaatgeneesmiddel voor de behandeling van recidief/refractair mantelcellymfoom (R/R MCL). De RMAT-status is ingestel...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch